3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Gestational Trophoblastic Disease
5
Rhabdomyosarcoma
4
Sarcoma
3
Melanoma
3
Testicular Neoplasms
1
Teratoma, Ovarian
1
Sarcoma, Ewing
1
Sarcoma, Alveolar Soft Part
1
Rhabdoid Tumor
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Neoplasms, Germ Cell and Embryonal
1
Lymphoma
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia
1
Hydatidiform Mole, Invasive
1
Histiocytoma, Malignant Fibrous
1
Dermatofibrosarcoma
1
Choroid Plexus Neoplasms
1
Choriocarcinoma
1
Central Nervous System Neoplasms
1
Brain Neoplasms
1
Blast Crisis
1
Interventions
Etoposide
10
Cisplatin
9
Cyclophosphamide
7
etoposide phosphate
5
Paclitaxel
5
Ifosfamide
5
Granulocyte Colony-Stimulating Factor
5
Carboplatin
5
fludarabine
4
Sirolimus
4
Gemcitabine
4
pembrolizumab
3
fludarabine phosphate
3
Sunitinib
3
Mesna
3
Melphalan
3
Filgrastim
3
Drug Therapy
3
Brentuximab Vedotin
3
Bleomycin
3
Bevacizumab
3
Automobiles
3
tremelimumab
2
sodium thiosulfate
2
pegfilgrastim
2
lutetium Lu 177 dotatate
2
durvalumab
2
Vorinostat
2
Stem Cell Transplantation
2
Oxaliplatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neoplasms, Germ Cell and Embryonal
×
Dactinomycin
×
Clear all
NCT06309732
2024-03-13
GAMEC-II
Queen Mary University of London
Phase 2
Completed
36 enrolled